Shunwei Capital
Wentao Wu is mainly responsible for investment execution in HealthTech/MedTech sectors. Prior to joining Shunwei, he was engaged in HealthTech/MedTech investment at China Growth Capital. Prior to that, he was engaged in basic and clinical research in regenerative medicine and immunotherapy at Peking University Third Hospital.
Wentao has led the investment of several projects in the field of new drugs and medical devices, including Farbers Therapeutics, ReviR Therapeutics, Renerval Biotheraputics, Neurodom Medical, ZD Medical, Singleron Biotechnologies, InxMed, Health Biotech, 4B Biotechetc.
Wentao received his bachelor's degree from Wuhan University and master's degree from Peking University Health Science Center.
This person is not in any teams
This person is not in any offices
Shunwei Capital
Shunwei Capital is a premier venture capital firm specializing in early to growth-stage investments in disruptive business models. They invest in mobile Internet, Internet+, consumer IoT, smart manufacturing, deep technology and rural Internet. Shunwei's investment portfolio comprises Xiaomi, 17zuoye, Meicai, iQiyi, NIO, Ninebot, Huolala, ShareChat, and other premium companies in China and internationally.